Table 4.
Comparison between patients according to the response treatment.
| Group A 30 pt (Peg-IFN-α + RBV + Placebo) | Group B 30 pt (Peg-IFN-α + RBV + Resveratrol) | |||||
|---|---|---|---|---|---|---|
| Pretreatment | SVR | Non R | Pretreatment | SVR | Non R | |
| 14 | 16 | 19 | 11 | |||
| General Health Questionnaire (GHQ) | 28.1 ± 12.4 | 26.7 ± 10.9 °A* | 29.7 ± 11.8 °A* | 29.1 ± 16.1 | 20.8 ± 14.2 °°A* | 32.8 ± 14.9 °°A* |
| Profile of Mood States (POMS) | 184.2 ± 13.7 | 175.1 ± 12.0 °A** | 180.0 ± 13.8 °B* | 187.2 ± 12.4 | 174.4 ± 11.8 °°°A*** | 194.0 ± 12.1 °°°B* |
| Pittsburgh Sleep Quality Inventory (PSQI) | 8.0 ± 3.1 | 7.5 ± 2.4 °°°A* | 11.0 ± 2.5 °°°A** | 8.2 ± 2.9 | 6.0 ± 2.1 °°°A* | 10.8 ± 2.4 °°°A** |
| Epworth Sleepiness Scale (ESS) | 12.1 ± 2.2 | 9.2 ± 2.3 °°B*** | 12.0 ± 2.0 °°A* | 12.8 ± 2.4 | 7.4 ± 2.2 °°°B*** | 11.9 ± 2.1 °°°A* |
SVR: Sustained Viral Response; Non R: Non Responders; Comparison within groups: * NS; ** p < 0.05; *** p < 0.001; Comparison SVR-Non R within groups: ° NS; °° p < 0.05; °°° p < 0.001; Comparison between groups: A NS; B p < 0.05; C p < 0.001; There were no significant differences between groups at baseline.